Truist raised the firm’s price target on Penumbra (PEN) to $330 from $315 and keeps a Buy rating on the shares. The company’s Q1 revenue outperformance was led by another strong U.S. Thrombectomy performance, while its margin control helped power a solid EPS beat, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $330 from $320 at UBS
- Penumbra price target raised to $330 from $315 at RBC Capital
- Penumbra price target raised to $325 from $316 at Baird
- Penumbra price target raised to $320 from $305 at BTIG
- Penumbra’s Strong Q1 Performance and Strategic Positioning Justify Buy Rating Despite Conservative FY25 Guidance